Investors are closely watching Eli Lilly & Company (LLY) as the pharmaceutical giant prepares to release its latest quarterly report later this week. Market watchers are predicting strong results driven by the strong demand of Lilly's blockbuster treatments, particularly the diabetes franchise. However, there are also concerns about potential chall